Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody
Open Access
- 22 November 2004
- journal article
- guideline
- Published by Wiley in American Journal of Hematology
- Vol. 77 (4) , 346-350
Abstract
Achieving adequate hemostasis in patients with hemophilia and high‐titer inhibitor antibodies remains a challenge despite the development of plasma‐derived and recombinant therapies to bypass the inhibitory effect. A group of hemophilia treaters met to examine the factors that influence physician choices among the very costly and cumbersome available therapies. Specific knowledge deficits in need of prospective research were identified with respect to the rational treatment of inhibitor patients. Am. J. Hematol. 77:346–350, 2004.Keywords
This publication has 25 references indexed in Scilit:
- Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusionThe Lancet, 2004
- Control of bleeding in patients with haemophilia A with inhibitors: a systematic reviewHaemophilia, 2003
- The Evidence behind Inhibitor Treatment with Porcine Factor VIIIPathophysiology of Haemostasis and Thrombosis, 2002
- Evolving perspectives in product safety for haemophiliaHaemophilia, 2002
- Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse eventsHaemophilia, 2002
- On the treatment of hemorrhage in patients with hemophilia and associated inhibitorsTransfusion, 2001
- Therapeutic choices for patients with hemophilia and high‐titer inhibitorsAmerican Journal of Hematology, 2001
- Definitions in HemophiliaThrombosis and Haemostasis, 2001
- Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerationsHaemophilia, 1999
- Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitorsHaemophilia, 1999